Literature DB >> 28440715

GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism.

Samer Tannus1,2, Yechiel Burke1, Christopher R McCartney3, Shahar Kol1,4.   

Abstract

The use of GnRH agonist to trigger final oocyte maturation in GnRH-antagonist in vitro fertilization (IVF) cycles has been shown to significantly reduce or even eliminate the risk of ovarian hyperstimulation syndrome (OHSS) by inducing rapid luteolysis early in the luteal phase. The exact mechanism of this early luteolysis is still widely unknown. Since luteinizing hormone (LH) has a major role in corpus luteum support, we sought to explore the pattern of LH secretion early in the luteal phase. Ten high risk patients for developing OHSS and triggered with GnRH agonist were included. Frequent blood sampling (every 20 min for 6 h) to measure LH, estradiol and progesterone was done on the day of oocyte collection (n = 5, Group 1) and on the day of embryo transfer, 48 h after oocyte collection (n = 5, Group 2). We found that the mean LH concentration and its secretion rate decreased significantly in Group 2 compared to Group 1. Both groups had similar number of LH pulses characterized by very small amplitude. In Group 2, there was a steady significant decrease in estradiol and progesterone over time. The results of this study show that LH secretion deviates significantly from normal physiologic pattern, which can explain, at least in part, the post-GnRH-agonist trigger early luteolysis mechanism.

Entities:  

Keywords:  GnRH agonist; GnRH antagonist; luteolysis; ovarian stimulation; ovulation triggering

Mesh:

Substances:

Year:  2017        PMID: 28440715     DOI: 10.1080/09513590.2017.1318275

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  Systematic Review of Ovarian Activity and Potential for Embryo Formation and Loss during the Use of Hormonal Contraception.

Authors:  Donna Harrison; Cara Buskmiller; Monique Chireau; Lester A Ruppersberger; Patrick P Yeung
Journal:  Linacre Q       Date:  2019-01-03

2.  Luteal Coasting and Individualization of Human Chorionic Gonadotropin Dose after Gonadotropin-Releasing Hormone Agonist Triggering for Final Oocyte Maturation-A Retrospective Proof-of-Concept Study.

Authors:  Barbara Lawrenz; Suzan Samir; Nicolas Garrido; Laura Melado; Nils Engelmann; Human M Fatemi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-15       Impact factor: 5.555

Review 3.  Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.

Authors:  Juan Carlos Castillo; Thor Haahr; María Martínez-Moya; Peter Humaidan
Journal:  Ups J Med Sci       Date:  2020-05-04       Impact factor: 2.384

4.  No significant long-term complications from inadvertent exposure to gonadotropin-releasing hormone agonist during early pregnancy in mothers and offspring: a retrospective analysis.

Authors:  Huan Wu; Xiaoyan Xu; Cong Ma; Yiran Zhou; Shanai Pei; Hao Geng; Ye He; Qianhua Xu; Yuping Xu; Xiaojin He; Ping Zhou; Zhaolian Wei; Xiaofeng Xu; Yunxia Cao
Journal:  Reprod Biol Endocrinol       Date:  2021-03-20       Impact factor: 5.211

5.  Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.

Authors:  Dzhamilyat Abdulkhalikova; Eda Vrtacnik Bokal; Martin Stimpfel; Primoz Ciglar; Sara Korosec
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

6.  Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment.

Authors:  Lise Haaber Thomsen; Ulrik Schiøler Kesmodel; Claus Yding Andersen; Peter Humaidan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-19       Impact factor: 5.555

Review 7.  Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review.

Authors:  Jing Zhao; Jie Hao; Yanping Li
Journal:  Reprod Health       Date:  2022-01-22       Impact factor: 3.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.